Coming Soon
MiniCeive
MiniCeive is a compact laboratory tool that enables fast and practical magnetic separation and liquid handling using magnet-based tubes and containers.
AutoCeive Coming Soon
Get Better with FAR Better
End-to-end automation for cell isolation, sample preparation and cell-based gene therapy manufacturing.
Empowering the future of research, drug testing and point-of-care treatments.
FAR: Filtrate Alternate Return
Whole Blood Processing for research and treatment
By replacing centrifugation and manual handling with acoustophoresis and column-free magnetic separation, our closed systems automate cell processing within a single fluidic path. Preserving cell viability, limiting cell exhaustion, and accelerating workflows across research, cell therapy, and point-of-care manufacturing, including CAR-T.
Coming Soon
AutoCeive
Isolates target cells directly from whole blood, leukopak, or PBMC samples using acoustophoresis and high-gradient magnetic separation. AutoCeive automates sample processing from input to ready-to-use target cell output within a closed workflow.
R&D Stage
TheraCeive
A programmable cell therapy manufacturing platform automating cell isolation, activation, transduction, and expansion. Compatible with whole blood and leukopak starting materials, and designed to enable safe, overnight manufacturing workflows.
R&D Stage
FAR Better
A programmable point-of-care cell therapy manufacturing platform supporting both viral and non-viral gene delivery from whole blood starting material. Designed to enable single-day vein-to-vein workflows by automating manufacturing and quality control while eliminating the need for invasive apheresis procedures.
Interested in being among the first to try our products?
Join our waitlist for early access and priority pre-orders.
Our Technology
Target Cell Enrichment & Isolation
Target cells are selectively captured using antibody-coated acoustomagnetic microspheres engineered for manipulation by both acoustic waves and magnetic field gradients. This dual-mode approach enables controlled enrichment and high-precision separation within a closed workflow, followed by integrated microsphere removal before purified, bead-free cells are collected.
Sample Preparation
The sample is mixed with selective and dual-use acoustomagnetic microspheres in specialized flow channels designed to promote efficient binding to target cells.
Cell Isolation
The sample is processed using both acoustic and magnetic filtration, where acoustic forces provide pre enrichment, especially for whole blood samples, and magnetic gradients isolate the microsphere bound target cells.
Debeading & Medium Exchange
Before collection, the microspheres are removed from the isolated cells and a buffer exchange is performed to prepare the final cell product.
Delivery
Isolated cells are delivered in the buffer or culture medium of choice, ready for downstream use with high purity and efficient recovery.
AutoCeive Features
Isolates desired cells from fluid sample using an immunomagnetic cell separation system.
Processes high numbers of cells in short notice, while being cost-efficient.
Offers an ideal alternative for cell biology and research laboratories.
Laboratory equipment and reagents now available at our products page!
"Cure is not far away, as long as you and I are willing to take things a little further."
What do you need?
Tell us about the solution you’re looking for. Our team is here to help you find the most suitable option with the quality and performance your work demands.
Contact UsOur Vision
Automated ex vivo non-viral CAR-T manufacturing from whole blood
Target cells are selectively captured using antibody-coated acoustomagnetic microspheres engineered for manipulation by both acoustic waves and magnetic field gradients. This dual-mode approach enables controlled enrichment and high-precision separation within a closed workflow, followed by integrated microsphere removal before purified, bead-free cells are collected.
Elimination of invasive leukapheresis:
Enables manufacturing directly from whole blood, avoiding apheresis procedures and reducing dependence on specialized equipment and trained personnel.
Point-of-care manufacturing:
Allows CAR-T products to be generated locally at hospitals or treatment centers, minimizing transport, cryopreservation, and delays.
Future-ready non-viral CAR-T compatibility:
Non-viral gene delivery can reduce dependence on complex viral vector manufacturing while enabling more flexible, scalable, and potentially multiplexed genetic engineering strategies for next-generation CAR-T therapies.
Simplified, standardized production:
Closed automation reduces manual handling, contamination risk, operator variability, and process-to-process inconsistency.
FAR Better™ Features
Automated Cell Processing & Isolation
In-Line Gene Transfection
Integrated QC & Product Delivery
From whole blood to a ready to use gene therapy product through one closed and automated platform.